Table 1 Clinical information on the GSE40272 prostate cancer cohort
Patient feature | High ADAM19 (n) | Low ADAM19 (n) | Total (n) |
|---|---|---|---|
All cases | Â | Â | 77 (100Â %) |
 ADAM19 evaluated |  36 (50.7 %) |  35 (49.3 %) | 71 (92.2 %) |
Age at diagnosis | Â | Â | Â |
 ≤54 | 7 (43.8 %) | 9 (56.3 %) | 16 (22.5 %) |
 55-64 | 14 (45.2 %) | 17 (54.8 %) | 31 (43.7 %) |
 ≥ 65 | 15 (62.5 %) | 9 (37.5 %) | 24 (33.8 %) |
Cancer stage | Â | Â | Â |
 II | 4 (80 %) | 1 (20 %) | 5 (7 %) |
 III | 23 (46.9 %) | 26 (53.1 %) | 49 (69 %) |
 IV | 7 (47.7 %) | 8 (53.3 %) | 15 (21.1 %) |
 Unknown | 2 (100 %) | 0 (0 %) | 2 (2.8 %) |
Gleason score | Â | Â | Â |
 6 | 7 (47.7 %) | 8 (53.3 %) | 15 (21.1 %) |
 7 | 26 (55.3 %) | 21 (44.7 %) | 47 (66.2 %) |
 8 | 1 (33.3 %) | 2 (66.7 %) | 3 (4.2 %) |
 9 | 1 (20 %) | 4 (80 %) | 5 (7 %) |
 Unknown | 1 (100 %) | 0 (0 %) | 1 (1.4 %) |
PSA levels (ng/mL) | Â | Â | Â |
 < 5 | 15 (45.5 %) | 18 (54.5 %) | 33 (46.5 %) |
 5-6.9 | 12 (80 %) | 3 (20 %) | 15 (21.1 %) |
 ≥ 7 | 7 (35 %) | 13 (65 %) | 20 (28.2 %) |
 Unknown | 2 (66.7 %) | 1 (33.3 %) | 3 (4.2 %) |
Tumour recurrence | Â | Â | Â |
 Yes | 5 (29.4 %) | 12 (70.6 %) | 17 (23.9 %) |
 No | 29 (56.9 %) | 22 (43.1 %) | 51 (71.8 %) |
 Unknown | 2 (66.7 %) | 1 (33.3 %) | 3 (4.2 %) |